James Mulay Sells 11,145 Shares of CG Oncology (NASDAQ:CGON) Stock

by · The Cerbat Gem

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) Director James Mulay sold 11,145 shares of the business’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $52.47, for a total value of $584,778.15. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

CG Oncology Price Performance

CGON stock traded down $1.14 during mid-day trading on Tuesday, reaching $52.58. 989,712 shares of the company traded hands, compared to its average volume of 1,898,937. The company has a fifty day moving average price of $41.63 and a 200-day moving average price of $35.61. CG Oncology, Inc. has a 52-week low of $14.80 and a 52-week high of $57.40. The company has a market capitalization of $4.24 billion, a P/E ratio of -25.77 and a beta of 1.35.

CG Oncology (NASDAQ:CGON – Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.57). The firm had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.07 million. As a group, analysts forecast that CG Oncology, Inc. will post -1.31 EPS for the current year.

Institutional Trading of CG Oncology

Institutional investors have recently added to or reduced their stakes in the business. Winthrop Capital Management LLC purchased a new stake in shares of CG Oncology during the second quarter valued at approximately $38,000. Strengthening Families & Communities LLC purchased a new stake in CG Oncology in the 3rd quarter worth approximately $40,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of CG Oncology by 15.6% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock valued at $77,000 after buying an additional 398 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of CG Oncology by 15.2% during the second quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock valued at $85,000 after acquiring an additional 433 shares in the last quarter. Finally, CWM LLC lifted its stake in CG Oncology by 193.5% in the second quarter. CWM LLC now owns 6,193 shares of the company’s stock worth $161,000 after acquiring an additional 4,083 shares during the period. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on CGON. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $82.00 price target on shares of CG Oncology in a report on Monday. Morgan Stanley set a $93.00 target price on CG Oncology in a research report on Friday. Guggenheim began coverage on CG Oncology in a report on Tuesday, October 7th. They issued a “buy” rating and a $90.00 price target on the stock. Truist Financial lifted their price target on CG Oncology from $62.00 to $66.00 and gave the company a “buy” rating in a research report on Friday. Finally, Wedbush began coverage on shares of CG Oncology in a research report on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price objective on the stock. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $65.58.

View Our Latest Stock Analysis on CGON

CG Oncology Company Profile

(Get Free Report)

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.

See Also